Additional data have provided stronger evidence supporting the notion that targeting cytokines like IL-12 or IL-23, which activate ILCs to produce IL-17 and IFN-γ, could be a superior approach in the treatment of Crohn’s disease [159]. This evidence concerns the gene IFNG and Crohn disease.